Centerpoint Advisors’s DexCom DXCM Stock Holding History

Centerpoint Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-4	Closed	–	–	473
2023 Q3	$0	Hold	4	–	–	﹤0.01%	571
2023 Q2	$1K	Hold	4	–	–	﹤0.01%	493
2023 Q1	$0	Buy	+4	New	+$448	﹤0.01%	577

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Centerpoint Advisors's DXCM Position: Q4 2023 in Review

Centerpoint Advisors sold out of DexCom (DXCM) in Q4 2023, closing a stake of 4 shares.

Centerpoint Advisors first reported a position in DXCM in Q1 2023 and held it in 3 quarters. The position peaked at $1K in Q2 2023. 974 funds tracked by Wall St. Rank hold DXCM as of Q4 2023.

Centerpoint Advisors reported no remaining DexCom position as of Q4 2023 after selling out during the quarter.
Centerpoint Advisors sold 4 DexCom shares in Q4 2023.
Centerpoint Advisors first reported a position in DexCom in Q1 2023 and held it in 3 quarters.
Centerpoint Advisors's DexCom position peaked at $1K in Q2 2023.
974 funds tracked by Wall St. Rank held DexCom as of Q4 2023.

Based on Centerpoint Advisors's 13F filing for Q4 2023, filed 16 Jan 2024.